The Queensland University of Technology’s (QUT) ATGC has entered into a partnership with non-profit research organisation Omico and the PrOSPeCT programme to offer personalised cancer treatment clinical trials in Australia.
This project will provide 1,600 cancer patients in Queensland with free access to personalised tumour analyses for a period of 18 months, potentially matching them with new treatment trials.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The PrOSPeCT programme, managed by Omico, has secured a $185m public-private funding commitment, including investments from the Australian Government, the New South Wales Government and various industry partners.
It aims to enhance cancer care in the country by creating a network for precision genomic testing and trials, which could lead to reduced treatment and testing costs for patients with cancer.
The ATGC was earlier selected as an Australian testing site for genomic sequencing, which is organised by PrOSPeCT and is a key contributor of genomic reports to the programme.
ATGC Genomics deputy director, associate professor Paul Leo said: “This strategic collaboration with Omico has the potential to transform the landscape of cancer care in Queensland, bringing us closer to our objective of providing precision medicine to every cancer patient in Queensland.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The project provides advanced genomic profiling of cancers to inform tailored treatment strategies and, whenever possible, grants patients access to cutting-edge clinical trials featuring drug combinations optimised for their specific cancer type.”
The latest development is in line with Omico’s plans to establish a network of clinical trial sites to offer new therapeutic options for cancer patients.
QUT professor Ken O’Byrne said: “The programme will offer testing services to patients in regional and remote centres, helping to improve access to state-of-the-art molecular diagnostics and clinical trials across diverse geographical regions.
“The ultimate goal is to establish a sustainable model for precision oncology, thus alleviating some of the financial burdens associated with oncology care while, most importantly, improving outcomes for patients.”
